BRAIN, SKELETAL MUSCLE AND PLATELET HOMOGENATE MITOCHONDRIAL FUNCTION IN PARKINSON'S DISEASE

MANN, V. M., COOPER, J. M., KRIGE, D., DANIEL, S. E., SCHAPIRA, A. H. V., MARSDEN, C. D.·1992·Brain
DOI 10.1093/brain/115.2.333

Cited by (345)

Items 101–200 of 345

  1. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models
    Hiroki Takeuchi, Takashi Yanagida, Masatoshi Inden, Kazuyuki Takata, Yoshihisa Kitamura, Kentaro Yamakawa, Hideyuki Sawada, Yasuhiko Izumi, Noriyuki Yamamoto, Takeshi Kihara et al. · 2008 · Journal of Neuroscience Research
  2. The Mechanisms by Which the Ketone Body D-β-Hydroxybutyrate May Improve the Multiple Cellular Pathologies of Parkinson's Disease
    Nicholas G. Norwitz, Michele T. Hu, Kieran Clarke · 2019 · Frontiers in Nutrition
  3. Replication of mitochondrial DNA occurs throughout the mitochondria of cultured human cells
    J Magnusson · 2003 · Experimental Cell Research
  4. mt4216C variant in linkage with the mtDNA TJ cluster may confer a susceptibility to mitochondrial dysfunction resulting in an increased risk of Parkinson's disease in the Irish
    Owen A. Ross · 2003 · Experimental Gerontology
  5. Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease—resemblance to the effect of amphetamine drugs of abuse
    Rita Perfeito, Teresa Cunha‐Oliveira, Ana Cristina Rego · 2012 · Free Radical Biology and Medicine
  6. A Mitochondrial Etiology of Neurodegenerative Diseases: Evidence from Parkinson's Disease
    Э. К. Хуснутдинова, I. R. Gilyazova, Eduardo Ruiz‐Pesini, Olga A. Derbeneva, Rita Igorevna Khusainova, Irina M. Khidiyatova, Rim V. Magzhanov, Douglas C. Wallace · 2008 · Annals of the New York Academy of Sciences
  7. Cortical glucose metabolism in Parkinson's disease without dementia
    Jamie L. Eberling, Brian C. Richardson, Bruce Reed, Nicola Wolfe, William Jagust · 1994 · Neurobiology of Aging
  8. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity
    Schulz, Jörg B., Ross Henshaw, D., Matthews, Russell T., Flint Beal, M. · 1995 · Experimental Neurology
  9. Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease
    Yumin Wang, Luyan Gao, Jichao Chen, Qiang Li, Liang Huo, Yanchao Wang, Hongquan Wang, Jichen Du · 2021 · Frontiers in Pharmacology
  10. The Role of Mitochondria in the Pathogenesis of Neurodegenerative Diseases
    Giovanni Manfredim, M. Flint Beal · 2000 · Brain Pathology
  11. Multiple Antioxidants in the Prevention and Treatment of Parkinson’s Disease
    Kedar Nath Prasad, William C. Cole, Bipin Kumar · 1999 · Journal of the American College of Nutrition
  12. Nicotinic Receptor-Mediated Neuroprotection in Neurodegenerative Disease Models
    Shun Shimohama · 2009 · Biological and Pharmaceutical Bulletin
  13. Mitochondrial DNA sequence analysis of four Alzheimer's and Parkinson's disease patients
    Michael D. Brown, John M. Shoffner, Yoon L. Kim, Albert S. Jun, Brett H. Graham, Margaret F. Cabell, Daniel S. Gurley, Douglas C. Wallace · 1996 · American Journal of Medical Genetics
  14. Neuronal pathology in Parkinson?s disease
    Jörg Bernhard Schulz · 2005 · Cell and Tissue Research · Retracted
  15. Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease
    Rosa, Alexandra Isabel, Duarte-Silva, Sara, Silva-Fernandes, Anabela, Nunes, Maria João, Carvalho, Andreia Neves, Rodrigues, Elsa, Gama, Maria João, Rodrigues, Cecília Maria Pereira, Maciel, Patrícia, Castro-Caldas, Margarida · 2018 · Molecular Neurobiology
  16. Tetrahydrobiopterin Scavenges Superoxide in Dopaminergic Neurons
    Ken Nakamura, Vytautas P. Bindokas, Devanand Kowlessur, Martyna Elas, Sheldon Milstien, Jeremy D. Marks, Howard J. Halpern, Un Jung Kang · 2001 · Journal of Biological Chemistry
  17. Metabolic inhibition and low internal ATP activate K-ATP channels in rat dopaminergic substantia nigra neurones
    Jochen Roeper, Frances Mary Ashcroft · 1995 · Pflügers Archiv - European Journal of Physiology
  18. Transcribe to Survive: Transcriptional Control of Antioxidant Defense Programs for Neuroprotection in Parkinson’s Disease
    Joanne Clark, David K. Simon · 2008 · Antioxidants and Redox Signaling
  19. Animal models of Parkinson’s disease in rodents induced by toxins: an update
    Étienne C. Hirsch, Günter U. Höglinger, Estelle Rousselet, Tilo Breidert, Karine Parain, Jean Féger, Merle Ruberg, Annick Prigent, Charles Cohen‐Salmon, Jean‐Marie Launay · 2003 · Journal of neural transmission. Supplementum
  20. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease
    Catherine Mytilineou, P. Werner, S. Molinari, Alessandro Di Rocco, G. Cohen, Melvin D. Yahr · 1994 · Journal of Neural Transmission - Parkinsons Disease and Dementia Section
  21. Dementia in Parkinson's disease is associated with enhanced mitochondrial complex I deficiency
    Ariana P. Gatt, Olivia F. Duncan, Johannes Attems, Paul T. Francis, Clive G. Ballard, J.E. Bateman · 2016 · Movement Disorders
  22. Mitochondrial Dysfunction: The Road to Alpha-Synuclein Oligomerization in PD
    A. Raquel Esteves, Daniela M. Arduíno, Diana Filipa Silva, Catarina Resende Oliveira, Sandra M. Cardoso · 2011 · Parkinson s Disease
  23. Oxidative stress in Parkinson's disease
    Anthony H.V. Schapira · 1995 · Neuropathology and Applied Neurobiology
  24. α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease
    Fanni F. Geibl, Martin T. Henrich, Zhong Xie, Enrico Zampese, Jun Ueda, Tatiana Tkatch, David L. Wokosin, Elena Nasiri, Constantin A. Grotmann, Valina Lynn Dawson et al. · 2024 · Molecular Neurodegeneration
  25. Neuronal pathology in Parkinson?s disease
    Jörg Bernhard Schulz, Björn H. Falkenburger · 2004 · Cell and Tissue Research · Retracted
  26. Deep brain stimulation of the subthalamic nucleus in Parkinson's Disease 1993 – 2003: where are we 10 years on?
    Keyoumars Ashkan, Bradley A. Wallace, BA Bell, Alim‐Louis Benabid · 2004 · British Journal of Neurosurgery
  27. [29] Platelet-mediated transformation of human mitochondrial DNA-less cells
    Anne Chomyn · 1996 · Methods in enzymology on CD-ROM/Methods in enzymology
  28. Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP+-induced mitochondrial dysfunctions in neuronal cells
    Ying Piao, Hyo Geun Kim, Myung Sook Oh, Youngmi Kim Pak · 2011 · Biochimica et Biophysica Acta (BBA) - General Subjects
  29. Ghrelin is neuroprotective in Parkinson’s disease: molecular mechanisms of metabolic neuroprotection
    Jacqueline A. Bayliss, Zane Bruce Andrews · 2013 · Therapeutic Advances in Endocrinology and Metabolism
  30. Cell Death Pathways in Parkinson's Disease: Role of Mitochondria
    Zhi Yao, Nicholas William Wood · 2009 · Antioxidants and Redox Signaling
  31. Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two‐dimensional resolution: Normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities
    Hermann Schägger · 1995 · Electrophoresis
  32. Oxidative stress and Parkinson's disease
    Peter G. Jenner · 2007 · Handbook of clinical neurology
  33. Effects of creatine treatment on the survival of dopaminergic neurons in cultured fetal ventral mesencephalic tissue
    Robert H. Andres, Alexander W. Huber, Uwe Schlattner, Alberto Pérez-Bouza, Sandra H. Krebs, Rolf Walter Seiler, Theo Wallimann, H.R. Widmer · 2005 · Neuroscience
  34. Effect of coenzyme Q10 on the mitochondrial function of skin fibroblasts from Parkinson patients
    Kirstin Winkler‐Stuck, Falk R. Wiedemann, Claus‐W. Wallesch, Wolfram S. Kunz · 2004 · Journal of the Neurological Sciences
  35. Congenital encephalomyopathy and adult-onset myopathy and diabetes mellitus: different phenotypic associations of a new heteroplasmic mtDNA tRNA glutamic acid mutation.
    Michael G. Hanna, Isabelle P. Nelson, Mary G. Sweeney, J Allen D Cooper, Peter Watkins, JOHN A. MORGAN-HUGHES, A. E. Harding · 1995 · Europe PMC (PubMed Central)
  36. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease
    A. Hartley, Jonathan M. Cooper, Anthony H.V. Schapira · 1993 · Brain Research
  37. Understanding the Multiple Role of Mitochondria in Parkinson’s Disease and Related Disorders: Lesson From Genetics and Protein–Interaction Network
    Valentina Nicoletti, Giovanni Palermo, Eleonora Del Prete, Michelangelo Mancuso, Roberto Ceravolo · 2021 · Frontiers in Cell and Developmental Biology
  38. Common Mechanisms Underlying α-Synuclein-Induced Mitochondrial Dysfunction in Parkinson’s Disease
    Tahereh Sohrabi, Behnaz Mirzaei-Behbahani, Ramin Zadali, Mitra Pirhaghi, Ludmilla A. Morozova‐Roche, Ali Akbar Meratan · 2023 · Journal of Molecular Biology
  39. Crosstalk between Nrf2 signaling and mitochondrial function in Parkinson's disease
    Navneet Ammal Kaidery, Manuj Ahuja, Bobby Thomas · 2019 · Molecular and Cellular Neuroscience
  40. NADPH and Mitochondrial Quality Control as Targets for a Circadian-Based Fasting and Exercise Therapy for the Treatment of Parkinson’s Disease
    William M. Curtis, William A. Seeds, Mark P. Mattson, Patrick C. Bradshaw · 2022 · Cells
  41. Decreased mitochondrial bioenergetics and calcium buffering capacity in the basal ganglia correlates with motor deficits in a nonhuman primate model of aging
    Pandya, Jignesh D., Grondin, Richard, Yonutas, Heather M., Haghnazar, Hamed, Gash, Don M., Zhang, Zhiming, Sullivan, Patrick G. · 2015 · Neurobiology of Aging
  42. Platelet mitochondrial respiratory chain function in Parkinson's disease
    C. I. Blake, E. Spitz, Maureen A. Leehey, Barry J. Hoffer, Sally J. Boyson · 1997 · Movement Disorders
  43. Mitochondrial dysfunctions in Parkinson's disease
    Clément Gautier, Olga Corti, Alexis Brice · 2013 · Revue Neurologique
  44. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production
    Erkki Nissinen, Petri Kaheinen, Kai E. Penttilä · 1997 · European Journal of Pharmacology
  45. Lesions outside the CNS in Parkinson's disease
    Ruth Djaldetti, Nirit Lev, Eldad Melamed · 2009 · Movement Disorders
  46. Mitochondrial toxins and neurodegenerative diseases
    Antonio Ayala · 2006 · Frontiers in bioscience
  47. Muscle modifications in Parkinson's disease: myoelectric manifestations
    Bruno Rossi, Gabriele Siciliano, Maria Chiara Carboncini, Maria Laura Manca, R. Massetani, Paolo Viacava, ALBERTO MURATORIO · 1996 · Electroencephalography and Clinical Neurophysiology/Electromyography and Motor Control
  48. Mitochondrial respiratory chain function in multiple system atrophy
    M. Gu, M. T. Gash, J Allen D Cooper, Gregor Karl Wenning, S. E. Daniel, Niall Patrick Quinn, C. DAVID MARSDEN, Anthony H.V. Schapira · 1997 · Movement Disorders
  49. Neurodegenerative Diseases: Neurotoxins as Sufficient Etiologic Agents?
    Christopher A. Shaw, Günter U. Höglinger · 2007 · NeuroMolecular Medicine
  50. Mitochondrial Membrane Potential in Aging Cells
    Mary M. Sugrue, W. G. Tatton · 2001 · Neurosignals
  51. Mitophagy and the Brain
    Natalie Swerdlow, Heather Wilkins · 2020 · International Journal of Molecular Sciences
  52. Using Human Pluripotent Stem Cell–Derived Dopaminergic Neurons to Evaluate Candidate Parkinson’s Disease Therapeutic Agents in MPP+ and Rotenone Models
    Peng, Jun, Liu, Qiuyue, Rao, Mahendra S., Zeng, Xianmin · 2013 · SLAS Discovery
  53. Mitochondrial Dysfunction in Neurodegeneration
    J Allen D Cooper, Anthony H.V. Schapira · 1997 · Journal of Bioenergetics and Biomembranes
  54. Parkinson disease: primacy of age as a risk factor for mitochondrial dysfunction
    Theodore B. VanItallie · 2008 · Metabolism
  55. A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease
    D.J. Taylor, David Krige, P. R. J. Barnes, Graham John Kemp, Maria T Carroll, Vincent M. Mann, J Allen D Cooper, C. DAVID MARSDEN, Anthony H.V. Schapira · 1994 · Journal of the Neurological Sciences
  56. Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson?s disease
    Winkler-Stuck, K., Kirches, E., Mawrin, C., Dietzmann, K., Lins, H., Wallesch, C.-W., Kunz, W. S., Wiedemann, F. R. · 2005 · Journal of Neural Transmission
  57. Mitochondrial therapies for Parkinson's disease
    Bobby Thomas, M. Flint Beal · 2010 · Movement Disorders
  58. Metabolism of Glutathione S-Conjugates: Multiple Pathways
    Arthur J.L. Cooper, Marie H. Hanigan · 2015 · Elsevier eBooks
  59. Autosomal dominant progressive external ophthalmoplegia: Distribution of multiple mitochondrial DNA deletions
    Moslemi, Ali-Reza, Melberg, Atle, Holme, Elisabeth, Oldfors, Anders · 1999 · Neurology
  60. Creatine Supplementation Improves Dopaminergic Cell Survival and Protects against MPP+ Toxicity in an Organotypic Tissue Culture System
    Robert H. Andres, Angélique Ducray, Alberto Pérez-Bouza, Uwe Schlattner, Alexander W. Huber, Sandra H. Krebs, Rolf Walter Seiler, Theo Wallimann, Hans Ruedi Widmer · 2005 · Cell Transplantation
  61. Mitochondrial function in neurodegeneration and ageing
    Anthony H.V. Schapira, J Allen D Cooper · 1992 · Mutation Research/DNAging
  62. Nicotinic Acetylcholine Receptor Signaling in Neuroprotection
    Akinori Akaike, Shun Shimohama, Yoshimi Misu · 2018 · Springer eBooks
  63. Tissue- and Cell-Specific Mitochondrial Defect in Parkin-Deficient Mice
    Maria G. Damiano, Clément Gautier, Anne‐Laure Bulteau, Rosa Ferrando-Miguel, Caroline Gouarné, Marc Giraudon‐Paoli, Rebecca M. Pruss, Françoise Auchère, Caroline L'Hermitte-Stead, Frédéric Bouillaud et al. · 2014 · PLoS ONE
  64. Mitochondrial Dysfunction in Neurodegenerative Disorders and Ageing
    Christopher Turner, Anthony H.V. Schapira · 2001 · Advances in experimental medicine and biology
  65. Mitochondrial Function and Dynamics in Neural Stem Cells and Neurogenesis: Implications for Neurodegenerative Diseases.
    Patrícia Coelho, Lígia Fão, S. Mota, A. Rego · 2022 · Ageing Research Reviews
  66. Adaptation within mitochondrial oxidative phosphorylation supercomplexes and membrane viscosity during degeneration of dopaminergic neurons in an animal model of early Parkinson's disease
    Katarzyna Z. Kuter, Manuela Kratochwil, Klemencja Berghauzen-Maciejewska, Urszula Głowacka, Michiru D. Sugawa, Krystyna Ossowska, Norbert A. Dencher · 2016 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  67. Untitled work
    2000 · 10.1002/1097-4547(20000915)61:6
  68. Oxidative stress in skin fibroblasts cultures from patients with Parkinson's disease
    Pilar del Hoyo, Alberto García‐Redondo, Fernando Bustos, José Antonio Molina, Youssef Sayed, Hortensia Alonso‐Navarro, Luis Caballero, Joaquı́n Arenas, José A. G. Agúndez, Félix Javier Jiménez‐Jiménez · 2010 · BMC Neurology
  69. Reduced platelet glutamate uptake in Parkinson's disease
    Carlo Ferrarese, C Zoia, Nicoletta Pecora, Roberto Piolti, Maura Frigo, G. Bianchi, Gessica Sala, Barbara Begni, Roberto Riva, Lodovico Frattola · 1999 · Journal of Neural Transmission
  70. Genomic convergence to identify candidate genes for Parkinson disease: SAGE analysis of the substantia nigra
    Maher Noureddine, Yi‐Ju Li, Joelle M. van der Walt, Robert Walters, Rita M. Jewett, Hong Xu, Tianyuan Wang, Jeffrey W. Walter, Burton L. Scott, Christine Hulette et al. · 2005 · Movement Disorders
  71. Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson’s disease? A critical reappraisal
    Nitya Subrahmanian, Matthew J. LaVoie · 2021 · Brain Research
  72. Substrate specificity of human glutamine transaminase K as an aminotransferase and as a cysteine S-conjugate β-lyase
    Arthur J.L. Cooper, John Thomas Pinto, Boris F. Krasnikov · 2008 · Archives of Biochemistry and Biophysics
  73. Mitochondrial Complex Inhibitors Preferentially Damage Substantia Nigra Dopamine Neurons in Rat Brain Slices
    Petra Teresia Bywood, Stephen Mark Johnson · 2002 · Experimental Neurology
  74. Increased mitochondrial superoxide dismutase activity in Parkinson's disease but not amyotrophic lateral sclerosis motor cortex
    Aleksandar Radunović, Weyler Galvão Pôrto, Sophie Zeman, P. Nigel Leigh · 1997 · Neuroscience Letters
  75. In vivo vulnerability of dopamine neurons to inhibition of energy metabolism
    Gail Duffy Zeevalk, Lawerence Manzino, James Hoppe, Patricia K. Sonsalla · 1997 · European Journal of Pharmacology
  76. α-Synuclein Aggregation: A Link Between Mitochondrial Defects and Parkinson's Disease?
    Seung‐Jae Lee · 2003 · Antioxidants and Redox Signaling
  77. Protection Against Dopaminergic Neurodegeneration in Parkinson’s Disease–Model Animals by a Modulator of the Oxidized Form of DJ-1, a Wild-type of Familial Parkinson’s Disease–Linked PARK7
    Masatoshi Inden, Yoshihisa Kitamura, Kazunori Takahashi, Kazuyuki Takata, Natsuko Ito, Rina Niwa, Risa Funayama, Kaneyasu Nishimura, Takashi Taniguchi, Toshio Honda et al. · 2011 · Journal of Pharmacological Sciences
  78. Management of the aging risk factor for Parkinson's disease
    Oliver T. Phillipson · 2013 · Neurobiology of Aging
  79. Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
    Gaetano Serviddio, Antonino Davide Romano, Tommaso Cassano, Francesco Bellanti, Emanuele Altomare, Gianluigi Vendemiale · 2011 · Current Pharmaceutical Design
  80. MITOCHONDRIAL COMPLEX I, II/III, AND IV ACTIVITIES IN FAMILIAL AND SPORADIC PARKINSON'S DISEASE
    Hasmet Ayhan Hanagasi, DILEK AYRIBAS, Kemal Baysal, Murat Emre · 2005 · International Journal of Neuroscience
  81. Cyanide Enhancement of Dopamine-Induced Apoptosis in Mesencephalic Cells Involves Mitochondrial Dysfunction and Oxidative Stress
    Douglas C. Jones, Krishnan Prabhakaran, Li Li, Palur G. Gunasekar, Yan Shou, Joseph L. Borowitz, Gary E. Isom · 2003 · NeuroToxicology
  82. The Microbiome-Mitochondria Dance in Prodromal Parkinson’s Disease
    Sandra M. Cardoso, Nuno Empadinhas · 2018 · Frontiers in Physiology
  83. Quantitative study of mitochondrial complex I in platelets of parkinsonian patients
    Blandini, Fabio, Nappi, Giuseppe, Timothy Greenamyre, J. · 1998 · Movement Disorders
  84. Paullinia cupana Mart. var. Sorbilis protects human dopaminergic neuroblastoma SH-SY5Y cell line against rotenone-induced cytotoxicity
    Diêgo Madureira de Oliveira, George Emilio Barreto, Pablo Galeano, Juan Ignacio Romero, Mariana Inés Holubiec, Maria Sol Badorrey, Francisco Capani, Lisandro Diego Giraldez Alvarez · 2010 · Human & Experimental Toxicology
  85. Interactions among nitric oxide and Bcl‐family proteins after MPP+ exposure of SH‐SY5Y neural cells I: MPP+ increases mitochondrial NO and Bax protein
    Jameel Dennis, James P. Bennett · 2003 · Journal of Neuroscience Research
  86. Aging, cellular senescence and Parkinson's disease
    Yue Ma, Madalynn L. Erb, Darren J. Moore · 2025 · Journal of Parkinson s Disease
  87. VPS35 and the mitochondria: Connecting the dots in Parkinson's disease pathophysiology
    Gianni Cutillo, David K. Simon, Simona Eleuteri · 2020 · Neurobiology of Disease
  88. The detection of preclinical Parkinson's disease: What is the role of positron emission tomography?
    Guy V. Sawle · 1993 · Movement Disorders
  89. Parkin affects mitochondrial function and apoptosis in neuronal and myogenic cells
    Yukiko Kuroda, Takao Mitsui, Makoto Kunishige, Toshio Matsumoto · 2006 · Biochemical and Biophysical Research Communications
  90. Defects of cytochrome c oxidase in the substantia nigra of Parkinson's disease: An immunohistochemical and morphometric study
    Kyoko Itoh, Serge Weis, Parviz Mehraein, Josef Müller‐Höcker · 1997 · Movement Disorders
  91. Respiratory‐chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients
    Miguel Angel Martín, José Antonio Molina, F J Jiménez-Jiménez, Julián Benito‐León, Miguel Ortí Pareja, Yolanda Campos, Joaquı́n Arenas, The Grupo Centro de Trastornos del Movimiento · 1996 · Neurology
  92. Rapid Communication Muscle Mitochondrial ATP Production in Progressive Supranuclear Palsy
    Donato A. Di Monte, Yadollah Harati, Joseph J. Jankovic · 1994 · Journal of Neurochemistry
  93. Current status of biomarker research in neurology
    Jiří Polívka, Jiří Polívka, Kristýna Krakorová, Marek Peterka, Ondřej Topolčan · 2016 · The EPMA Journal
  94. Mitochondrial dysfunction – a pathogenetic factor in Parkinson’s disease
    Heinz Reichmann, Bernd Janetzky · 2000 · Journal of Neurology
  95. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
    A. Morgan, Daniel Rees, Z. Andrews, J. Davies · 2017 · Neuropharmacology
  96. Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics
    Goutam Chandra, Rajesh Anantha Shenoi, Resmi Anand, Usha Rajamma, Kochupurackal P. Mohanakumar · 2017 · Journal of Chemical Neuroanatomy
  97. L ‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain
    J Allen D Cooper, S. E. Daniel, C. DAVID MARSDEN, Anthony H.V. Schapira · 1995 · Movement Disorders
  98. Nitric oxide and DOPAC-induced cell death: From GSH depletion to mitochondrial energy crisis
    Carla Nunes, Rui M. Barbosa, Leonor M. Almeida, João A.N. Laranjinha · 2011 · Molecular and Cellular Neuroscience
  99. What Process Causes Nigral Cell Death in Parkinson’s Disease?
    Peter G. Jenner · 1992 · Neurologic Clinics
  100. Testosterone ameliorates age-related brain mitochondrial dysfunction
    Wensheng Yan, Tianyun Zhang, Yunxiao Kang, Guoliang Zhang, Xiaoming Ji, Xu Feng, Geming Shi · 2021 · Aging